Objective We sought to test the hypothesis that Polygenic Risk Scores (PRSs) have strong capacity to discriminate cases of ankylosing spondylitis (AS) from healthy controls and individuals in the community with chronic back pain. Methods PRSs were developed and validated in individuals of European and East Asian ethnicity, using data from genome-wide association studies in 15 585 AS cases and 20 452 controls. The discriminatory values of PRSs in these populations were compared with other widely used diagnostic tests, including C-reactive protein (CRP), HLA-B27 and sacroiliac MRI. Results In people of European descent, PRS had high discriminatory capacity with area under the curve (AUC) in receiver operator characteristic analysis of 0.924.This was significantly better than for HLA-B27 testing alone (AUC=0.869), MRI (AUC=0.885) or C-reactive protein (AUC=0.700). PRS developed and validated in individuals of East Asian descent performed similarly (AUC=0.948). Assuming a prior probability of AS of 10% such as in patients with chronic back pain under 45 years of age, compared with HLA-B27 testing alone, PRS provides higher positive values for 35% of patients and negative predictive values for 67.5% of patients. For PRS, in people of European descent, the maximum positive predictive value was 78.2% and negative predictive value was 100%, whereas for HLA-B27, these values were 51.9% and 97.9%, respectively. Conclusions PRS have higher discriminatory capacity for AS than CRP, sacroiliac MRI or HLA-B27 status alone. For optimal performance, PRS should be developed for use in the specific ethnic groups to which they are to be applied.
基金:
Arthritis Research UKVersus Arthritis [19536, 18797]; Wellcome TrustWellcome TrustEuropean Commission [076113]; Oxford Comprehensive Biomedical Research Centre ankylosing spondylitis chronic disease cohort [A91202]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31821003]; National Key Research and Development Project [2018AAA0100302]; Shanghai Municipal Key Clinical Specialty [shslczdzk02602]; Shanghai Science and Technology Development Funds [2020-SH-XY-2]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LD18H120001LD]; Health Research Council, New ZealandHealth Research Council of New Zealand; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); National Institute for Health Research (NIHR) Leeds Biomedical Research CentreNational Institute for Health Research (NIHR); Agence Nationale de Recherche GEMISAFrench National Research Agency (ANR) [ANR-10-MIDI-0002]; AbbvieAbbVie; PfizerPfizer; UCBUCB Pharma SA; NHMRCNational Health and Medical Research Council of Australia; ARCAustralian Research Council; National Health and Medical Research Council (Australia)National Health and Medical Research Council of Australia [566938, 569829, 1024879]; Australian Cancer Research Foundation; Rebecca Cooper Medical Research Foundation; National Institute for Health Research Oxford Musculoskeletal Biomedical Research Unit; NIHR Thames Valley Comprehensive Local Research; Abbott LaboratoriesAbbott Laboratories; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College LondonGeneral Electric
第一作者机构:[1]Queensland Univ Technol, Ctr Genom & Personalised Hlth, Sch Biomed Sci, Fac Hlth,Translat Res Inst, Woolloongabba, Qld, Australia
共同第一作者:
通讯作者:
通讯机构:[2]Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Rheumatol & Immunol, Shanghai, Shanghai, Peoples R China[27]Wenzhou Med Univ, Affiliated Hosp 1, Ctr Precis Med, Wenzhou, Zhejiang, Peoples R China[37]Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China[38]Tsinghua Univ, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China[39]Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England[40]Kings Coll London, London SE1 9RT, England[*1]NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, SE1 9RT, United Kingdom[*2]Second Mil Med Univ, Changzheng Hosp, Dept Rheumatol & Immunol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Li Zhixiu,Wu Xin,Leo Paul J.,et al.Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis[J].ANNALS OF THE RHEUMATIC DISEASES.2021,80(9):1168-1174.doi:10.1136/annrheumdis-2020-219446.
APA:
Li, Zhixiu,Wu, Xin,Leo, Paul J.,De Guzman, Erika,Akkoc, Nurullah...&Brown, Matthew A..(2021).Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.ANNALS OF THE RHEUMATIC DISEASES,80,(9)
MLA:
Li, Zhixiu,et al."Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis".ANNALS OF THE RHEUMATIC DISEASES 80..9(2021):1168-1174